Director Eckhardt Sue Gail sold EXELIXIS ($EXEL) shares three times on the open market over the last year, for a total of nearly $1 million. Her most recent sale occurred on February 13, 2026. These transactions rank her 5,000th among 11,678 insiders by sale value, well below the average of $8.6 million across 6.4 transactions per seller. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2026 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | S | Common Stock | 3856 | $43.79 | 17,524.0000 | 281,863,000 | 18.04% | 0.00% |
| June 2, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | S | Common Stock | 4 | $43.67 | 21,380.0000 | 296,132,000 | 0.02% | 0.00% |
| June 2, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | S | Common Stock | 18834 | $42.74 | 21,384.0000 | 296,132,000 | 46.83% | 0.01% |
| May 29, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | A | Common Stock | 9812 | $0.00 | 40,218.0000 | 296,132,000 | 32.27% | 0.00% |
| Feb. 14, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | S | Common Stock | 7712 | $35.01 | 34,262.0000 | 296,132,000 | 18.37% | 0.00% |
| Feb. 14, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | S | Common Stock | 3856 | $35.04 | 30,406.0000 | 296,132,000 | 11.25% | 0.00% |
| Feb. 14, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | M | Option (right to buy) | 7712 | $0.00 | 23,136.0000 | 296,132,000 | 25.00% | 0.00% |
| Feb. 14, 2025 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | M | Common Stock | 7712 | $23.24 | 41,974.0000 | 296,132,000 | 22.51% | 0.00% |
| June 5, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Eckhardt Sue Gail | Not found | A | Common Stock | 4000 | $0.00 | 16,000.0000 | 28,325,779 | 33.33% | 0.01% |
| June 5, 2024 | Syros Pharmaceuticals, Inc. | $SYRS | Eckhardt Sue Gail | Not found | A | Stock Option (right to buy) | 6000 | $0.00 | 6,000.0000 | 28,325,779 | 9999.99% | 0.02% |
| May 31, 2024 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | A | Common Stock | 18838 | $0.00 | 34,262.0000 | 321,464,000 | 122.13% | 0.01% |
| Jan. 5, 2024 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | A | Common Stock | 15424 | $0.00 | 15,424.0000 | 321,464,000 | 9999.99% | 0.00% |
| Jan. 5, 2024 | EXELIXIS, INC. | $EXEL | Eckhardt Sue Gail | Director | A | Option (right to buy) | 30848 | $0.00 | 30,848.0000 | 321,464,000 | 9999.99% | 0.01% |